Hilltop Holdings Inc. Raises Holdings in Sanofi (NASDAQ:SNY)

Hilltop Holdings Inc. boosted its stake in Sanofi (NASDAQ:SNY) by 47.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,224 shares of the company’s stock after purchasing an additional 3,313 shares during the period. Hilltop Holdings Inc.’s holdings in Sanofi were worth $589,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Stablepoint Partners LLC boosted its holdings in shares of Sanofi by 0.8% during the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock worth $1,377,000 after purchasing an additional 189 shares during the period. PDS Planning Inc lifted its holdings in Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after buying an additional 200 shares during the period. Eagle Ridge Investment Management lifted its holdings in Sanofi by 3.8% in the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock worth $321,000 after buying an additional 203 shares during the period. Financial Advocates Investment Management increased its stake in shares of Sanofi by 3.4% during the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after buying an additional 206 shares during the period. Finally, Angeles Investment Advisors LLC raised its holdings in shares of Sanofi by 1.9% during the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after acquiring an additional 210 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $48.51 on Friday. The business has a fifty day simple moving average of $52.25 and a two-hundred day simple moving average of $52.11. The firm has a market capitalization of $123.11 billion, a P/E ratio of 24.75, a P/E/G ratio of 1.22 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the prior year, the company earned $2.55 earnings per share. The business’s revenue was up 12.3% compared to the same quarter last year. On average, equities analysts forecast that Sanofi will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on SNY shares. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Sanofi currently has an average rating of “Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.